Physician profile
Amor Royer
NPI 1265920557
$4,750.76
in general payments reported to CMS, 2019-2025
25 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.13 · 2021: $316 · 2022: $1,189 · 2023: $742 · 2024: $1,276 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.25 | 2021-2025 | Rinvoq, Skyrizi |
| Medtronic, INC. | $463.26 | 2022-2024 | Pillcam, Gi Genius |
| E.R. Squibb & Sons, L.L.C. | $460.95 | 2021-2022 | |
| Janssen Biotech, INC. | $447.47 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $303.45 | 2023-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $278.90 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $274.85 | 2020-2024 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $206.59 | 2022-2024 | |
| Genzyme Corporation | $147.80 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $142.22 | 2025 | |
| Phathom Pharmaceuticals, INC. | $135.24 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.22 | 2024-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $82.82 | 2025 | Rezdiffra |
| Qol Medical, LLC | $63.46 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $54.97 | 2025 | Vowst, Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.96 | 2025 | Omvoh |
| Pfizer INC. | $51.17 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $50.60 | 2025 | Iqirvo |
| Celltrion USA INC. | $44.58 | 2025 | Vegzelma |
| Amgen INC. | $41.15 | 2025 | Uplizna |
| Boston Scientific Corporation | $27.06 | 2021-2023 | Wallflex Duodenal |
| Braintree Laboratories, INC. | $17.05 | 2024 | Suflave, Sutab |
| Novo Nordisk INC | $15.74 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.46 | 2021 | |
| Organon LLC | $11.54 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amor Royer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.